Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT06427512

Mechanisms Underlying Cardiovascular Consequences Associated With COVID-19 and Long COVID

Mechanisms Underlying Cardiovascular Consequences Associated With COVID-19 and Long COVID - Characterizing Long COVID Phenotypes Using Physiological and Molecular Studies

Status
Withdrawn
Phase
Study type
Observational
Enrollment
0 (actual)
Sponsor
Columbia University · Academic / Other
Sex
All
Age
19 Years – 74 Years
Healthy volunteers

Summary

AIM 1. Characterize cardiovascular phenotypes of long COVID by cardiopulmonary, meta-bolic, and cardiac mechanical/physiological responses to exercise and microvascular vasomotor function. AIM 2. Identify intercellular signaling between immune cells and cardiac cells associated with microvascular phenotypes of long COVID.

Detailed description

As many as 40-60% of patients who recovered from mild or moderate acute COVID have reported what is now called long COVID - multiple, persistent or recurrent symptoms lasting 6-9 months (or longer) following initial illness.1-4 Fatigue, dyspnea, and chest pain are the most common symptoms. Others include palpitations, lightheadedness, and syncope. All these cardiovascular symptoms can be debilitating, resulting in worse quality of life and morbidity.5, 6 Treatment options are limited.

Conditions

Timeline

Start date
2022-03-01
Primary completion
2025-03-01
Completion
2025-03-01
First posted
2024-05-24
Last updated
2024-05-24

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT06427512. Inclusion in this directory is not an endorsement.